Crohn's Disease Newswire (Page 7)

Crohn's Disease Newswire (Page 7)

Comprehensive Real-Time News Feed for Crohn's Disease. (Page 7)

Results 121 - 140 of 4,130 in Crohn's Disease

  1. Enterome's EB8018, a First-in-class Drug Candidate Targeting Crohn's...Read the original story w/Photo

    Sep 20, 2017 | PR Newswire

    ENTEROME SA, a pioneer of innovative therapies for microbiome-related diseases, is pleased to announce the successful completion of the first Phase 1 clinical study with its lead candidate EB8018, a small molecule designed to block FimH, as a potential new orally-administered treatment for Crohn's disease. EB8018 was found to be well tolerated in healthy volunteers across a wide range of doses tested.

    Comment?

  2. Celgene: Sell-Off Is OverdoneRead the original story w/Photo

    Oct 26, 2017 | Seeking Alpha

    The company did post disappointing news with regard to Crohn's Disease and lowered its guidance, but I don't this should have resulted in a ~35% sell off. CELG remains highly speculative at these levels, but I'm willing to bet on shares as a part of the growth basket I've built within my overall portfolio.

    Comment?

  3. Some GI disorders get disproportionate share of U.S. research fundingRead the original story w/Photo

    Oct 26, 2017 | Reuters

    Gastrointestinal disorders such as Crohn's disease and Barrett's esophagus get a bigger slice of U.S. public research funding than other GI conditions that affect many more Americans, researchers say. Writing in the journal Gastroenterology, the study team questions how the National Institutes of Health makes spending decisions for GI research after finding no link between how many Americans are affected by a disease and the amount of money directed toward studying it.

    Comment?

  4. Why Celgene Corporation Tumbled TodayRead the original story w/Photo

    Oct 26, 2017 | Fox News

    ... will fall in the $2.6 billion to $2.8 billion range. The slower Otezla sales plus the loss of GED-0301 in Crohn's disease is clearly hurting the I&I category. Expectations for Celgene's oncology drugs also went down from more than $2.2 billion ...

    Comment?

  5. UPDATE 4-Celgene cuts 2020 outlook, Otezla sales disappoint; shares plungeRead the original story w/Photo

    Oct 26, 2017 | Reuters

    ... its long-time cash cow Revlimid for multiple myeloma and the surprise failure last week of an experimental Crohn's disease drug touted as a future multibillion-dollar product. Celgene shares fell by $23.23, or 19 percent, to $96.33. The stock's ...

    Comment?

  6. Study concludes that data supports switching from Remicade to biosimilar RenflexisRead the original story w/Photo

    Oct 26, 2017 | JD Supra

    ... from reference infliximab to SB2. Renflexis was approved by the FDA on April 21, 2017 for the treatment of Crohn's disease, pediatric Crohn's disease, ulcerative colitis (in adult patients), rheumatoid arthritis (in combination with methotrexate), ...

    Comment?

  7. Study concludes that data supports switching from RemicadeA to biosimilar RenflexisARead the original story w/Photo

    Oct 26, 2017 | jdsupra.com

    ... from reference infliximab to SB2. Renflexis was approved by the FDA on April 21, 2017 for the treatment of Crohn's disease, pediatric Crohn's disease, ulcerative colitis (in adult patients), rheumatoid arthritis (in combination with methotrexate), ...

    Comment?

  8. Celgene stock drops 19% on top drug's sluggish sales, cuts to long-term guidanceRead the original story w/Photo

    Oct 26, 2017 | MarketWatch

    ... was dealt another major blow just last week, when it announced it will abandon development efforts in Crohn's disease for its GED-0301 therapy. GED-0301, also called mongersen, was part of Celgene's inflammation and immunology development program, ...

    Comment?

  9. AbbVie Touts Late-Stage Psoriasis Drug Trial DataRead the original story w/Photo

    Oct 25, 2017 | BioSpace

    ... product. In addition to plaque psoriasis, risankizumab is also being assessed as a potential treatment for Crohn's disease, psoriatic arthritis and asthma. Future trials are planned to investigate risankizumab in ulcerative colitis. AbbVie is hoping ...

    Comment?

  10. Letters Page, October 26, 2017Read the original story w/Photo

    Oct 26, 2017 | South China Morning Post

    ... intramuscular (IM) injection of prednisone which provides the main relief to Crohn's sufferers. I have had Crohn's disease for 50 years and I am alive today because of self-treatment of prednisone IM injections during attacks of this very ...

    Comment?

  11. Body composition is associated with response to anti-TNF therapy in Crohn's diseaseRead the original story

    Oct 25, 2017 | GastroHep.com

    The body composition profile is associated with response to anti-TNF therapy in Crohn's disease and may offer an alternative dosing paradigm, reports the latest issue of the Alimentary Pharmacology & Therapeutics . Anti-tumor necrosis factor s form a major part of therapy in Crohn's disease and have a primary nonresponse rate of 10%-30% and a secondary loss of response rate of 5% per year.

    Comment?

  12. 'I lost several pregnancies over a period of six years' - mother...Read the original story w/Photo

    Oct 25, 2017 | Independent.ie

    ... did not think for one minute anything could go wrong. I did have an underlying health issue as I have Crohn's disease, but I was hopeful it would not interfere with the pregnancy, and all would be well. The first few weeks I had significant pain - ...

    Comment?

  13. Westville Lake artist finds post-stroke voice as Jupiter art directorRead the original story w/Photo

    Oct 25, 2017 | The Review

    ... a while and added that ailment to a laundry list of other health issues that included rheumatoid arthritis, Crohn's disease and fibromyalgia. However, she never lets life's hiccups hold her back and she continues to exhibit, create new work and has ...

    Comment?

  14. Detailed Study of the Europe Nutraceuticals MarketRead the original story

    Oct 18, 2017 | Emailwire.com

    ... values. Along with just providing nutrients, it deals with the gut complications as well such as, Crohn's disease, ulcerative colitis, and irritable bowel syndrome. Free sample of the report is available @ htt ...

    Comment?

  15. Protagonist Therapeutics, Inc. (PTGX) Lowered to "Hold" at Zacks Investment ResearchRead the original story w/Photo

    Oct 18, 2017 | AmericanBankingNews.com

    According to Zacks, "Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The Company's initial lead product candidates consists of PTG-100 and PTG-200, which have the potential to transform the existing treatment paradigm for inflammatory bowel disease, a GI disease consisting primarily of ulcerative colitis and Crohn's disease; PTG-300, an injectable hepcidin mimetic.

    Comment?

  16. Disabled man hits out at double-locked public toilets in SouthamptonRead the original story w/Photo

    Oct 17, 2017 | Daily Echo

    Andy Thorngate suffers from Crohn's disease - chronic bowel condition that causes severe inflammation of the digestive tract that means he needs to use the toilet more often than most people. The 34 year old has a radar key for toilets in the city to allow him to use the facilities even when they are locked to the general public.

    Comment?

  17. Confirmed: Broccoli improves digestive health and protects against toxins, reducing inflammationRead the original story w/Photo

    Oct 17, 2017 | NewsTarget.com

    ... Furthermore, this may lower the risk of developing diseases, such as different types of cancers and Crohn's Disease, brought about by inflammation in the lining of the gut. Results showed that the mice with a higher binding ability can endure ...

    Comment?

  18. Janssen Announces FDA Approval of Stelara (ustekinumab) for the...Read the original story w/Photo

    Oct 12, 2017 | Drugs.com

    ... methotrexate, and for the treatment of adult patients 18 years or older with moderately to severely active Crohn's disease who have already taken other medicines that did not work well enough or they could not tolerate it. At the Janssen ...

    Comment?

  19. Mouse data backs broccoli for better gut healthRead the original story w/Photo

    Oct 17, 2017 | NutraIngredients

    ... a According to the team, this approach could help prevent a variety of diseases, such as various cancers and Crohn's Disease, which is caused by inflammation in the lining of the gut. Perdew and his team used two genetic lines of mice in the study ...

    Comment?

  20. Results from Phase 2 Studies of Oral Ozanimod in Crohn's Disease and...Read the original story

    Oct 17, 2017 | Newkerala.com

    Summit, N.J., United States : Celgene Corporation today announced that phase 2 data of investigational compound ozanimod in Crohn's disease and ulcerative colitis will be presented at the World Congress of Gastroenterology at ACG2017 in Orlando. The studies include new data from the STEPSTONE study in patients with moderately to severely active Crohn's disease and long-term data from the open-label extension of the TOUCHSTONE study in patients with moderately to severely active ulcerative colitis .

    Comment?